Sergio Poli-Bigelli, Jose Rodrigues-Pereira, Alexandra D. Carides, Guoguang Julie Ma, Krista Eldridge, Anita Hipple, Judith K. Evans, Kevin J. Horgan, Francesca Lawson and On behalf of the Aprepitant Protocol 054 Study Group Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting Cancer 97
Article first published online: 29 MAY 2003 | DOI: 10.1002/cncr.11433
A large Phase III randomized trial was conducted to confirm the results of earlier studies, which suggested that the addition of aprepitant to standard dual therapy with a 5-hydroxytriptamine-3 antagonist and a corticosteroid would enhance protection against chemotherapy-induced nausea and vomiting (CINV). Compared with standard dual therapy, the addition of aprepitant was generally well tolerated and provided consistently superior protection against CINV in patients who were receiving highly emetogenic chemotherapy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.